Prime Medicine Inc (PRME) - News Archive

Prime Medicine s Pioneering Approach to Wilson s Disease: A Step Toward Transformative Genetic Therapies In a significant announcement that underscores the potential for revolutionary advancements in genetic therapies,...

Prime Medicine s Strategic Advancements in Genetic MedicinePrime Medicine Inc. is making waves in the biotechnology sector with its innovative approach to genetic medicine, capitalizing on its prime editing platform to...

Prime Medicine, a biotechnology company specializing in gene editing technologies, has announced a strategic research collaboration and licensing agreement with Bristol Myers Squibb (BMS), a leading biopharmaceutical fi...

Exsilio Debuts with $82M, Propelling Genetic Medicine ForwardIn a groundbreaking move, Exsilio, a biotech company, has recently made its debut in the field of genetic medicine. With a promising approach, the company aim...

Chronic Granulomatous Disease (CGD) is a rare genetic disorder that affects the innate immune system, leaving patients more susceptible to recurrent infections and inflammatory complications. The pioneering work of Prim...

In a significant development for chronic granulomatous disease (CGD) treatment, Prime Medicine s Investigational New Drug (IND) application for PM359 has gained clearance from the United States Food and Drug Administrat...

Cambridge-based biotechnology company, Prime Medicine, Inc. (Nasdaq: PRME), has successfully completed its underwritten upsized public offering, generating significant funds amounting to approximately $161.0 million. Th...

In a groundbreaking move, Prime Medicine, Inc. (Nasdaq: PRME), a leading biotechnology company dedicated to revolutionizing the field of genetic therapies, has announced the pricing of an underwritten upsized public off...

In an exciting development for the biotechnology industry, Prime Medicine, Inc. has announced the commencement of an underwritten public offering of $125.0 million worth of shares of its common stock. As a pioneering co...

Prime Medicine Receives $15 Million from Cystic Fibrosis Foundation to Accelerate Genetic Therapies for Cystic FibrosisCAMBRIDGE, Mass., Jan. 25, 2024 - Prime Medicine, Inc., a pioneering biotechnology company specializ...